Lymphoma, Non-Hodgkin's
Conditions
Brief summary
This study is being conducted to determine the safety, side effects, and response to a combination of an established high-dose chemotherapy regimen, plus the addition of Rituximab (which is a form of immunotherapy).
Detailed description
Combination chemotherapy is the standard treatment as initial therapy for advanced stage aggressive Non-Hodgkin's lymphoma (NHL). Standard chemotherapy cures less than 40% of patients. When patients relapse, they may be eligible to receive high-dose chemotherapy with autologous stem cell support. Multiple studies have shown the value of high-dose chemotherapy, with increased disease-free survival and overall survival, when compared with second-line conventional chemotherapy. Unfortunately high-dose chemotherapy is curative in less than half the patients who receive it, and other treatment strategies are needed to improve the cure rate. Another treatment option called immunotherapy is being tested in lymphoma patients. Immunotherapy involves attempts to use the immune system or products of the immune system to fight lymphoma. For example, NHL cells have a protein called CD20 on their surface. Rituximab is an antibody directed against the CD20 protein, which may result in the death of the lymphoma cell. Patients in this study will receive Rituximab to see if it is a safe treatment option for NHL patients.
Interventions
DRUGRituximab
Sponsors
University of Michigan Rogel Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Histologically documented, aggressive and/ or intermediate grade and high-grade B cell NHL, CD20 positive. * In relapse after primary conventional chemotherapy * Tumor sensitive (at least a partial response) to induction chemotherapy and/ or radiation therapy after treatment for relapse * Treatment of CNS or meningeal disease (cytology-negative CSF) if present * Treatment of CNS or meningeal disease (cytology-negative CSF) if present. * Cumulative total doxorubicin dosage \<500 mg/m2 * Performance score: 0-2 * Prior malignancies eligible if treated for cure and without active disease * Patients must not be pregnant or nursing. * Prior Immunotherapy is allowed * Signed Informed Consent * Absolute neutrophil count \> 1500/ µl, platelet count \>100,000/ µl * Bilirubin \<1.5 x normal, SGOT \<2.5 x normal * Serum creatinine \<1.5 mg/dl * Ejection fraction \> 45% or \> 40% with normal wall motion * HIV negative * FEV1, DLCO \> 50% predicted
Exclusion criteria
* Pregnant or nursing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess safety and toxicity after rituximab and high-dose chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Assess CD20 depletion in leukapheresis products after rituximab and high-dose chemotherapy, and monitor CD20 recovery post-transplant | — |
| Assess the response rate after rituximab and high-dose chemotherapy with autologous peripheral blood progenitor cell (PBPC) support, for patients with relapsed CD20+ Non-Hodgkin's lymphoma (NHL) | — |
| Assess progression-free and overall survival after rituximab and high-dose chemotherapy with PBPC support | — |
Countries
United States
Outcome results
None listed